NCT01419990View on ClinicalTrials.gov

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Oral Doses of GLPG0634 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

August 31, 2011

Primary Completion Date

October 31, 2011

Study Completion Date

October 31, 2011

Conditions
Healthy
Interventions
DRUG

GLPG0634

GLPG0634 300 mg oral capsules, qd, 10 days

DRUG

GLPG0634

GLPG0634 450 mg oral capsules, qd, 10 days

DRUG

Placebo

Placebo oral capsules, qd, 10 days

Trial Locations (1)

2060

SGS Stuivenberg, Antwerp

Sponsors

Lead Sponsor

Galapagos NV
All Listed Sponsors
lead

Galapagos NV

INDUSTRY